Otsuka Pharmaceutical
Otsuka Pharmaceutical Co., Ltd., commonly referred to as Otsuka, is a leading global healthcare company headquartered in Japan. Established in 1964, Otsuka has made significant strides in the pharmaceutical and nutraceutical industries, focusing on innovative solutions for mental health, oncology, and general healthcare. With a strong presence in regions such as North America, Europe, and Asia, Otsuka is renowned for its unique products, including the antipsychotic medication Abilify and the hydration solution Pocari Sweat. The company’s commitment to research and development has positioned it as a pioneer in addressing unmet medical needs. Otsuka's dedication to innovation and patient care has earned it a notable reputation in the global market, making it a key player in the pharmaceutical landscape.
DitchCarbon Score
How does Otsuka Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Otsuka Pharmaceutical's score of 60 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Otsuka Pharmaceutical's reported carbon emissions
In 2023, Otsuka Pharmaceutical reported total carbon emissions of approximately 123,190,000 kg CO2e for Scope 1 and about 30,537,000 kg CO2e for Scope 2 in Japan. Globally, the company disclosed Scope 1 emissions of around 109,739,000 kg CO2e, with Scope 2 emissions reported as 1,395,000 kg CO2e (market-based) and 128,012,000 kg CO2e (location-based). Additionally, Scope 3 emissions were significant, totalling approximately 664,646,000 kg CO2e, with major contributions from purchased goods and services (about 664,646,000 kg CO2e) and use of sold products (approximately 79,728,000 kg CO2e). Otsuka has set ambitious climate commitments, aiming for a 50% reduction in Scope 1 and 2 emissions by 2028 compared to 2017 levels. This target was accelerated from an original goal of 2030. The company is also working towards achieving net-zero emissions across all scopes by 2050, as part of its long-term environmental vision. The emissions data is sourced from Otsuka Holdings Co., Ltd., reflecting the company's commitment to transparency and accountability in its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 101,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 159,000,000 | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 866,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Otsuka Pharmaceutical is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
